(Q38184380)

30 August 2017

Biomarkers for gastric cancer: prognostic, predictive or targets of therapy? (English)

1 reference

30 August 2017

0 references

2

1 reference

30 August 2017

4

1 reference

30 August 2017

Cecília Durães

1

0 references

Raquel Seruca

object named as

Raquel Seruca

series ordinal

3

0 references

Fatima Carneiro

object named as

Fátima Carneiro

series ordinal

5

0 references

publication date

1 February 2014

1 reference

30 August 2017

12

1 reference

inferred from page(s)

published in

Virchows Archiv

1 reference

30 August 2017

464

1 reference

30 August 2017

3

1 reference

30 August 2017

367-378

1 reference

https://scigraph.springernature.com/pub.10.1007/s00428-013-1533-y

30 August 2017

0 references

cites work

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

21 January 2018

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Helicobacter pylori and gastric cancer: a new paradigm for inflammation-associated epithelial cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Hereditary gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Germline CDH1 deletions in hereditary diffuse gastric cancer families

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Clinical trials in gastric cancer and the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

New sentinel node mapping technologies for early gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Current questions for the treatment of advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Validation of the Royal Marsden hospital prognostic index in advanced esophagogastric cancer using individual patient data from the REAL 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Trastuzumab--mechanism of action and use in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Detection of kinase amplifications in gastric cancer archives using fluorescence in situ hybridization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

MET expression and amplification in patients with localized gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Efficacy of RAD001 (everolimus) against advanced gastric cancer with peritoneal dissemination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

The prevalence of PIK3CA mutations in gastric and colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

High-throughput mutation profiling identifies frequent somatic mutations in advanced gastric adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

MSI-L gastric carcinomas share the hMLH1 methylation status of MSI-H carcinomas but not their clinicopathological profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Oncogenic mutations in gastric cancer with microsatellite instability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

The clinicopathological features of gastric carcinomas with microsatellite instability may be mediated by mutations of different "target genes": a study of the TGFbeta RII, IGFII R, and BAX genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: results from a large international multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Prognostic and putative predictive biomarkers of gastric cancer for personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

The interaction of Ras with GTPase-activating proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Loss of functional E-cadherin renders cells more resistant to the apoptotic agent taxol in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Screening for gastric cancer in Asia: current evidence and practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Vital-dye enhanced fluorescence imaging of GI mucosa: metaplasia, neoplasia, inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Personalized colon cancer care in 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Frequent ki-ras mutations in gastric tumors of the MSI phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Somatic Mutations and Deletions of the E-Cadherin Gene Predict Poor Survival of Patients With Gastric Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00428-013-1533-Y

Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.

21 January 2018

1 reference

12 December 2020

Sentinel node mapping for gastric cancer: a prospective multicenter trial in Japan

1 reference

12 December 2020

Prognostic or Predictive? It's Time to Get Back to Definitions!

1 reference

12 December 2020

HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series.

1 reference

12 December 2020

The incidence and prognostic value of HER2 overexpression and cyclin D1 expression in patients with gastric or gastroesophageal junction adenocarcinoma in Israel

1 reference

12 December 2020

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

1 reference

12 December 2020

A review on biomarkers for prediction of treatment outcome in gastric cancer

1 reference

12 December 2020

Diffuse type advanced gastric cancer showing dismal prognosis is characterized by deeper invasion and emerging peritoneal cancer cell: the latest comparative study to intestinal advanced gastric cancer

1 reference

12 December 2020

Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma

1 reference

12 December 2020

Towards the goal of personalized medicine in gastric cancer--time to move beyond HER2 inhibition. Part I: Targeting receptor tyrosine kinase gene amplification

1 reference

12 December 2020

Sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor requires E-cadherin in esophageal cancer and malignant pleural mesothelioma

1 reference

12 December 2020

Evaluation of HER2-based biology in 1,006 cases of gastric cancer in a Japanese population

1 reference

12 December 2020

Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients

1 reference

12 December 2020

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial

1 reference

12 December 2020

Lack of microRNA-101 causes E-cadherin functional deregulation through EZH2 up-regulation in intestinal gastric cancer

1 reference

12 December 2020

Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target.

1 reference

12 December 2020

Gastroesophageal cancer: focus on epidemiology, classification, and staging

1 reference

12 December 2020

10.1007/S00428-013-1533-Y

Identifiers

DOI

1 reference

30 August 2017

1 reference

PubMed ID

24487788